Sign in

NCT05047315Completed

Evaluating a New Stool Based qPCR for Diagnosis of Tuberculosis in Children and People Living With HIV

Source: ClinicalTrials.gov · Last updated 6 Mar 2026

Brief summary (registry, in English)

Stool4TB aims to evaluate an innovative stool-based qPCR diagnostic platform (with the capacity to become a POC diagnostic tool) in the high TB and HIV burden settings of Mozambique, Eswatini and Uganda, under the hypothesis that it will narrow the extremely large TB case detection gap by improving TB confirmation rates in children and people living with HIV (PLHIV).

Status (registry)
Completed
Study type
Observational
Enrollment
1967 (actual)
First submitted
8 Sept 2021
Start date
1 Dec 2021
Primary completion date
17 Dec 2024
Lead sponsor
Barcelona Institute for Global Health
Diseases
Tuberculosis, HIV
NCT number
NCT05047315

What you commit to

  • Study type: Observational
  • Participants enrolled: 1967
  • From 1 Dec 2021 to the primary completion date, 17 Dec 2024
  • 3 sites in 3 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Receiving TB treatment for \>72 hours in previous 2 weeks

Other illness

  • History of TB treatment in the last year
  • Refusal to provide consent for study participation or HIV testing when status is unknown
  • Severe illness resulting in unstable condition
  • Absolute contra-indication to any of sampling procedures required by the study (ie: acute severe asthma, pertussis syndrome etc.)

Other

  • Participants will be excluded (both from study groups) if:

Who the study is looking for

  • Pediatric Cohort
  • \<8 years of age
  • Identified with suspected PTB defined as follows:
    • A child with ≥1 of the following criteria:
    • <!-- -->
    • Persistent unremitting cough (or cough significantly worse than usual in child with chronic lung disease including HIV-related) of \>2 weeks duration, unresponsive to a course of appropriate antibiotics (when clinically indicated)
    • Poor growth documented over the preceding 3 months \[clear deviation from a previous growth trajectory and/or documented crossing of centile lines in the preceding 3 months and/or; weight-for-age, or weight-for-height Z-score of ≤2 in the absence of information on previous/recent growth trajectory AND not responding to nutritional rehabilitation (or to antiretroviral therapy if HIV-infected)\]
    • Persistent unexplained lethargy or reduced playfulness/activity reported by the caregiver.
    • Persistent (\>1w) unexplained fever (\>38C), reported by a guardian or objectively recorded at least once;
    • In infants 0-60 days, also: unresponsive neonatal pneumonia or unexplained hepatosplenomegaly OR sepsis-like illness (all other more common causes excluded and/or not responding to appropriate therapy/ broad-spectrum antibiotics/antivirals).
    • OR
    • 2\) Any duration of cough/ wheeze/ acute pneumonia with ≥1:
  • TB exposure. Either: i) Documented/Reported exposure to a known TB source case (regardless of smear status) in previous 12months OR ii) immunological evidence: positive IGRA or positive TST (defined as \>5mm in HIV infected or severely malnourished, \>10 otherwise)
  • Chest radiograph suggestive of TB.
    • Adult Cohort (WHO definition of a HIV-positive presumptive TB case)
  • \> 15 years of age
  • Confirmed HIV infection (ELISA or molecular)
  • Presenting at any health facility with any of the following: cough, fever, night sweats or unintentional weight loss (any duration).

Age in the registry: 0 years to 8 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centro de investigação de Saúde de Manhiça
Coordinator of this site? Confirm its status
ManhiçaMozambiqueUnknown status
Baylor Eswatini Clinical Centre of Excellence (COE)
Coordinator of this site? Confirm its status
MbabaneEswatiniUnknown status
Makerere University
Coordinator of this site? Confirm its status
KampalaUgandaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.